| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Mustang Bio, Inc.$0.7
-0.04 (-5.85%)
D 29Pipeline Score Undervalued Pharma · Clinical
Market Cap
4.79 M
EPS
-0.48
P/E Ratio
-
Value Trade
56.55 K
SEC Financials
Q1 2026Dilution Risk
Operating CF
-1.01 M
Total Assets
16.58 M
Total Liabilities
7.99 M
Equity
8.60 M
D/E Ratio
12,345
2.13 %
Week
-14.3 %
1 Month
-27.39 %
3 Month
-46.43 %
6 Month
-99.97 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
16.26 M
Monthly Burn
336.00 K
Runway
46.4 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
62.03 K
52 Week Range
0.53 - 7
% held by Insiders
14.98 %
% held by Institutions
6.7 %
Enterprise Value
-11.47 M
Total Shares
6.73 M
Short %
1.65 %
Float Shares
6.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Mustang Bio, Inc.
496Total events
2Upcoming
77Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 2
Event history 494
Jun 2026
◆Topline ReadoutMB-106Clinical Data
Top-line data from pivotal Phase 2 WM trial expected as early as mid-2026
Waldenstrom macroglobulinemiasource ↗
Q2 2026
◆Topline ReadoutMB-106Clinical Data
Topline results from pivotal Phase 2 trial of MB-106 expected in second half of 2026
Waldenstrom macroglobulinemiasource ↗
Jul 7, 2025
▲Orphan Drug DesignationMB-101Designation
FDA granted Orphan Drug Designation for MB-101
recurrent diffuse and anaplastic astrocytoma and glioblastomasource ↗
Q3 2025
◆Trial InitiationMB-109Trial
Initiation of novel clinical trial for MB-109 (MB-108 + MB-101) expected in second half of 2025
recurrent glioblastoma and high-grade astrocytomassource ↗
Feb 27, 2025
▼Restructuring LayoffsCorporate
Exit of manufacturing facility lease and sale of fixed assets to AbbVie
Feb 6, 2025
Jan 16, 2025
▼Reverse Stock SplitCorporate
1-for-50 reverse stock split to comply with Nasdaq minimum bid price
2025
◆Trial InitiationMB-106Trial
Initiate pivotal Phase 2 trial in at least one additional B-cell malignancy in 2025
B-cell malignancysource ↗
Nov 7, 2024
▲Orphan Drug DesignationMB-108Designation
FDA grants Orphan Drug Designation for MB-108 in malignant glioma
malignant gliomasource ↗
Oct 25, 2024
Oct 24, 2024
Drug Pipeline Intelligence
D29
Pipeline Score $24M
Pipeline ValueUndervalued
Valuation Signal1
Drugs Scored5.0x
rNPV / MCap Top 32%
Micro Cap (rank 620 of 911)
Percentile RankMustang Bio, Inc. faces pipeline headwinds (29/100), with $96M risk-adjusted pipeline value, led by Chimeric Antigen Receptor T-Cell Therapy in Recurrent B-Cell Non-Hodgkin Lymphoma (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chimeric Antigen Receptor T-Cell Therapy Monoclonal antibody | Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | NCT03277729 | 17% | $96M | ACTIVE NOT_RECRUITING | 53 | - | - | Mar 1, 2039 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MB-106 | Waldenstrom macroglobulinemia | Phase 1/2 | 2024-06-17 | 90% overall response rate, 3 complete responses, 2 very good partial responses, 4 partial responses, 1 patient remains in complete remission at 31 months Read More | Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy Read More | |
MB-106 | Waldenstrom macroglobulinemia | Phase 1/2 | 2024-06-17 | 90% overall response rate, 3 complete responses, 2 very good partial responses, 4 partial responses, 1 patient remains in complete remission at 31 months Read More | Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy Read More | |
MB-106 | Waldenstrom macroglobulinemia | Phase 1/2 | 2024-06-17 | 90% overall response rate, 3 complete responses, 2 very good partial responses, 4 partial responses, 1 patient remains in complete remission at 31 months Read More | Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MBIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MBIO▲ +180.7%on this news
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
Mustang Bio has been granted Orphan Drug Designation by the FDA for MB-101, a CAR T-cell therapy targeting IL13Ra2, aimed at treating recurrent astrocytomas and glioblastoma. The designation is based on positive results from a Phase 1 trial, where 50% of patients achieved stable disease or better. The company is also exploring a combination therapy with MB-108 to enhance treatment efficacy. However, further development is contingent on securing additional funding.
Read more →MBIO▼ -9.4%on this news
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
Mustang Bio, Inc. has announced that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement. This follows a formal notice from Nasdaq confirming that the company meets all criteria for continued listing. Mustang previously satisfied the minimum bid price requirement, indicating a positive trajectory for the company.
Read more →MBIO▼ -27%on this news· ran to -38% by day 3shared move
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
Mustang Bio has announced the exit of its manufacturing facility lease in Worcester, Massachusetts, and the sale of fixed assets to AbbVie for $1 million. The company anticipates saving around $2 million in cash expenses over the next two years. Mustang is focusing on advancing its clinical trials, particularly with MB-109 for treating recurrent glioblastoma, expected to initiate in late 2025.
Read more →MBIOMustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
Mustang Bio, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. Following a recent public offering, the company believes it has met the necessary stockholders' equity for continued listing. However, a formal compliance determination from Nasdaq is still pending, and there is uncertainty regarding the outcome.
Read more →MBIO▲ +5.4%on this newsshared move
Mustang Bio Announces Closing of $8 Million Public Offering
Mustang Bio, Inc. has closed an $8 million public offering, issuing over 2.6 million shares and accompanying warrants. The proceeds will be used for working capital and corporate purposes. The offering was facilitated by H.C. Wainwright & Co. and follows the SEC's approval of their registration statement. However, the company faces various risks, including funding needs and potential delays in clinical trials.
Read more →MBIOMustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio, Inc. announced the pricing of a public offering of 2,657,807 shares at $3.01 each, along with warrants. The gross proceeds are expected to be around $8 million, which will be utilized for working capital and corporate purposes. The offering is subject to stockholder approval and customary closing conditions.
Read more →MBIO▼ -35.8%on this news· ran to -50% by day 3
Mustang Bio Announces Reverse Stock Split
Mustang Bio, Inc. announced a 1-for-50 reverse stock split of its common stock, effective January 16, 2025. This decision, approved by the Board of Directors, aims to meet Nasdaq's minimum bid price requirement. Following the split, the number of outstanding shares will decrease from approximately 64.8 million to about 1.3 million. Stockholders will receive cash payments for any fractional shares.
Read more →MBIOMustang Bio Receives Positive Listing Determination from Nasdaq
Mustang Bio, Inc. announced that the Nasdaq Hearings Panel approved its request for an extension to demonstrate compliance with continued listing criteria on The Nasdaq Capital Market. The company has until January 31, 2025, to meet the $1.00 bid price requirement and until February 18, 2025, for the $2.5 million stockholders' equity requirement. Mustang is exploring options to meet these criteria, but there is no guarantee of success. The company, focused on cell therapies for cancer treatment, faces financial uncertainties and risks associated with clinical trials.
Read more →MBIOMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
Mustang Bio has received Orphan Drug Designation from the FDA for MB-108, an HSV-1 oncolytic virus aimed at treating malignant glioma. The designation denotes special incentives, such as tax credits and market exclusivity. Ongoing Phase 1 clinical trials indicate that MB-108 is well tolerated in recurrent glioblastoma patients. The company aims to combine MB-108 with MB-101 CAR-T cell therapy to improve therapeutic outcomes, contingent on future funding and strategic partnerships.
Read more →MBIOMustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
Mustang Bio, Inc. has announced the exercise of certain existing warrants, resulting in gross proceeds of approximately $4 million. The agreement involves the purchase of nearly 17 million shares at an exercise price of $0.237 per share. Additionally, new warrants for the purchase of over 33 million shares will be issued, with a higher exercise price of $0.27 each. The funds will primarily be used for working capital and general corporate purposes, with the transaction expected to close on or around October 25, 2024.
Read more →MBIOMustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio, Inc. has successfully closed a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The offering involved the issuance of 6,130,000 shares at $0.41 per share and included unregistered warrants. The net proceeds from this offering are intended for working capital and general corporate purposes. This move may help the company to continue its focus on developing cell therapies for difficult-to-treat cancers.
Read more →MBIO▼ -34.1%on this newsshared move
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio, Inc. has announced a registered direct offering to issue 6,130,000 shares of common stock at a price of $0.41 per share, aiming to raise approximately $2.5 million. The offering, set to close around June 21, 2024, will include unregistered warrants to purchase additional shares. The funds will primarily support general corporate purposes and working capital. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
Read more →MBIO▲ +476.9%on this news· ran to +554% by day 1shared move
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
Mustang Bio has announced favorable updated data from its Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T therapy for Waldenstrom macroglobulinemia (WM). The trial reported a 90% overall response rate, with durable remissions observed, demonstrating the potential of MB-106 in treating this challenging blood cancer. Despite the promising results, the future of the MB-106 program is dependent on securing additional funding and developing strategic partnerships.
Read more →MBIO▲ +12.6%on this news
Mustang Bio Announces Closing of $4 Million Public Offering
Mustang Bio, Inc. announced the successful closing of a public offering, raising approximately $4 million from the sale of shares and warrants. This funding will be used for working capital and other corporate needs. The company also amended existing warrants to lower their exercise price significantly. If fully exercised, these warrants could result in an additional $12 million in gross proceeds for the company.
Read more →MBIOMustang Bio Announces Pricing of $4 Million Public Offering
Mustang Bio, Inc. has announced the pricing of a public offering, raising $4 million through the sale of approximately 16.9 million shares of common stock and associated warrants. The shares are priced at $0.237 each, with various series of warrants attached. The net proceeds from this offering will be allocated for working capital and corporate needs, as the offering is expected to close on or around May 2, 2024. Additionally, Mustang Bio plans to amend existing warrants from a previous offering to match this new exercise price. The company emphasizes their commitment to developing effective therapies during this funding acquisition.
Read more →MBIO▲ +10.6%on this news
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Mustang Bio, Inc. is planning to expand its CAR T-cell therapy platform with MB-106, targeting autoimmune diseases. They are in discussions with Fred Hutchinson Cancer Center to initiate a Phase 1 investigator-sponsored clinical trial in late 2024, leveraging promising safety and efficacy data from previous studies. The company believes that its CAR T-cell therapy can lead to improved patient outcomes in this new application, although there are inherent risks in the clinical trial process and the need for substantial funding.
Read more →MBIO▼ -7.2%on this news· ran to -20% by day 3
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Mustang Bio, Inc. reported its full-year financial results for 2023, highlighting significant developments in its clinical trials, particularly with MB-106. The company plans to initiate a registrational CAR-T trial targeting Waldenstrom macroglobulinemia, with expectations for FDA interactions in 2024. Despite demonstrating promising clinical data and partnerships, Mustang has faced a considerable decline in cash reserves and reported a net loss for the year. The upcoming RMAT designation from the FDA could enhance the development process for their therapies.
Read more →MBIOMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
Mustang Bio, Inc. will take part in the upcoming B. Riley Securities 4th Annual Oncology Conference on January 18, 2024. CEO Manuel Litchman is set to participate in a fireside chat, indicating a focus on sharing advancements in cell and gene therapies for treating difficult cancers and rare diseases. The event may enhance Mustang's visibility among investors and stakeholders in the oncology sector. A replay of the chat will be available following the event.
Read more →MBIO▼ -7.1%on this news
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
Mustang Bio presented updated clinical data for MB-106 at the ASH Annual Meeting, highlighting a robust safety and efficacy profile. Data from nine patients show a 100% complete response rate among those with follicular lymphoma, with no occurrences of severe cytokine release syndrome or neurotoxicity. This new data builds on prior results from a single-center trial, indicating consistent therapeutic benefits and feasibility of outpatient treatment. The company is planning to finalize a Phase 2 dose level and move forward with regulatory meetings early in 2024.
Read more →MBIOMustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Mustang Bio, Inc. reported third-quarter 2023 financial results highlighting advances in its clinical programs, particularly for MB-106, which has shown promising safety and efficacy in treating certain B-cell malignancies. The company plans to present further data at the upcoming ASH Annual Meeting and expects to pursue an accelerated registration strategy for Waldenstrom macroglobulinemia. Additionally, Mustang's investigational drug MB-109 received FDA clearance to initiate a Phase 1 trial for glioblastoma. Despite these advancements, Mustang's financial position has worsened, reflected in a significant year-over-year loss and decreasing cash reserves.
Read more →MBIOMustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
Mustang Bio, Inc. announced that data from its Phase 1/2 trial of MB-106, a CD20-targeted CAR-T cell therapy, has been selected for presentation at the upcoming ASH Annual Meeting. The trial involved heavily pre-treated patients with B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, demonstrating significant efficacy and safety. All patients showed CAR-T cell expansion and no severe toxicities were reported. The company looks forward to sharing more detailed results at the conference in December 2023.
Read more →MBIOMustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio, Inc. has announced the successful closing of a registered direct offering, generating approximately $4.4 million in gross proceeds. The offering consisted of 2,588,236 shares priced at $1.70 each, with concurrent issuance of unregistered warrants for additional shares. The funds are intended for working capital and general corporate needs, potentially enhancing Mustang's position in the biopharmaceutical sector. H.C. Wainwright & Co. acted as the exclusive placement agent for this offering.
Read more →MBIO▼ -10.2%on this newsshared move
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and
Mustang Bio announced the FDA's acceptance of its IND application for MB-109, a novel combination of MB-101 and MB-108 aimed at treating recurrent glioblastoma and high-grade astrocytoma. The company plans to initiate a Phase 1 clinical trial in 2024, focusing on evaluating the safety, tolerability, and efficacy of this combination therapy. Preclinical data suggest the regimen may improve treatment outcomes by reshaping the tumor microenvironment. The trial will take place at City of Hope and the University of Alabama at Birmingham.
Read more →MBIO▼ -10.2%on this newsshared move
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio, Inc. has announced a definitive agreement for a registered direct offering of approximately 2.6 million shares of common stock priced at $1.70 each, aiming to raise around $4.4 million. The offering, expected to close on October 30, 2023, includes unregistered warrants that can be exercised within five and a half years. Proceeds from the offering will be used for working capital and general corporate purposes. H.C. Wainwright & Co. acts as the exclusive placement agent for the deal.
Read more →MBIOMustang Bio to Participate in Upcoming September 2023 Investor Conferences
Mustang Bio, Inc. has announced its participation in two upcoming investor conferences in New York City, led by CEO Manuel Litchman. The company will present updates at the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023, and will participate in a panel at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2023. These events will feature one-on-one meetings for investors and are designed to enhance engagement with stakeholders. Webcasts of the presentations will be available on the company's website following the events.
Read more →MBIOMustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
Mustang Bio announced promising initial results from its Phase 1/2 clinical trial evaluating MB-106, a CAR-T cell therapy targeting indolent lymphoma. The data revealed complete responses in all four patients studied, including one previously treated with another CAR-T therapy. The trial's safety profile was favorable, with only mild cytokine release syndrome reported. An escalation of the treatment dose has been approved by the Safety Review Committee, indicating ongoing progress towards more extensive patient evaluations.
Read more →MBIOMustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Mustang Bio, Inc. reported its second-quarter financial results and highlighted advancements in its lead candidate MB-106, a CAR T cell therapy for hematologic malignancies. Notably, initial data from clinical trials suggest favorable safety and efficacy profiles, particularly in treating Waldenstrom macroglobulinemia, with an anticipated Phase 2 study starting potentially in early 2024. The company also announced a strategic partnership with uBriGene to enhance manufacturing and reduce operational costs. However, Mustang reported a significant drop in cash reserves and an increased net loss compared to the previous year.
Read more →MBIOMustang Bio to Participate in Two August 2023 Investor Conferences
Mustang Bio, Inc. announced its participation in two investor conferences scheduled for August 2023. CEO Manuel Litchman will provide a corporate update at the BTIG Virtual Biotechnology Conference on August 8 and participate in a fireside chat at the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17. These events present opportunities for Mustang Bio to engage with investors and discuss advancements in their therapies.
Read more →MBIOMustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
Mustang Bio, Inc. has successfully closed an amended asset purchase agreement with uBriGene (Boston) Biosciences, receiving $6 million upfront while retaining its manufacturing facility and staff during the lease transfer phase. The agreement allows Mustang to focus on its lead clinical programs, notably the CAR T therapy MB-106, while leveraging uBriGene's manufacturing capabilities. An additional contingent payment of $5 million is possible upon certain equity raises and lease assignments. The transaction is also subject to review by the U.S. Committee on Foreign Investment.
Read more →MBIOMustang Bio Announces Participation in Upcoming Scientific Meetings
Mustang Bio, Inc. has announced its participation in two significant scientific meetings: the 2nd In Vivo Engineering of Therapeutic Cells Summit and the 8th Annual CAR-TCR Summit, scheduled for July and August 2023 respectively. The company's management team will present on various topics related to cell and gene therapies, highlighting its focus on therapeutic innovations for cancer and rare diseases. These meetings provide a platform for Mustang Bio to share its research advancements and foster collaboration within the industry.
Read more →MBIOMustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
Mustang Bio announced positive final results from the follicular lymphoma cohort of its Phase 1/2 clinical trial for MB-106, a CD20-targeted CAR T-cell therapy. The study demonstrated a 95% overall response rate among 20 patients, with 80% achieving a complete response. Notably, higher doses yielded a 100% overall response rate. The safety profile was favorable, with no severe cytokine release syndrome events recorded. Upcoming data from a multicenter trial is also expected soon, further emphasizing the potential of MB-106.
Read more →MBIOMustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
Mustang Bio has reported promising updated results from its Phase 1/2 clinical trial of MB-106, a CAR T therapy for Waldenstrom macroglobulinemia. The trial demonstrated an overall response rate of 83%, with one patient achieving complete remission that has lasted for 22 months. Patients showed durable responses without initiating new anti-WM treatments post-MB-106 administration. The results highlight the potential of MB-106 to meet significant unmet needs in the treatment landscape, as current options for this condition remain limited.
Read more →MBIOMustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
Mustang Bio has announced a strategic partnership with uBriGene Biosciences, which includes the sale of its Worcester manufacturing facility for up to $11 million. This partnership aims to optimize Mustang's resources while focusing on its lead programs, MB-106, MB-109, and its in vivo CAR T platform technology. Furthermore, the company plans to reduce operating expenses significantly and expressed confidence in the efficacy of MB-106, which has shown a high response rate in ongoing trials. However, Mustang has decided to discontinue several other CAR T programs and pause enrollment for certain gene therapy trials as part of its strategic overhaul.
Read more →MBIOMustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Mustang Bio, Inc. reported its financial results for the first quarter of 2023, highlighting advancements in its lead clinical candidate MB-106. The CAR T cell therapy, aimed at treating relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, is showing promising early results in clinical trials, with a high overall response rate. However, the company reported a significant net loss and a decrease in cash reserves compared to the previous quarter, prompting concern about its financial stability. Upcoming presentations at major medical conferences are expected to provide additional insights into MB-106's efficacy and safety.
Read more →MBIOMustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
Mustang Bio, Inc. announced that Phase 1/2 trial data for MB-106, a CD20-targeted CAR T cell therapy, will be presented at two upcoming conferences. The data will specifically focus on patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. Presentations will take place at the EHA2023 Hybrid Congress and ICML, showcasing the therapy's clinical activity and safety profile. Mustang's collaboration with Fred Hutch enhances the development of this promising treatment.
Read more →MBIOMustang Bio Announces Reverse Stock Split Worcester, MA
Mustang Bio, Inc. announced a 15-for-1 reverse stock split aimed at maintaining compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The Board of Directors approved the reverse split, which will reduce the outstanding shares from approximately 109.4 million to about 7.3 million. This change will occur on April 4, 2023, with the common stock continuing to trade under the symbol 'MBIO'. The company is engaged in developing therapies for various serious diseases, which may help enhance its financial standing.
Read more →MBIOMustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
Mustang Bio, Inc. reported its financial results for the full year of 2022, highlighting significant progress in its cell and gene therapy programs. The company's lead candidate, MB-106, has shown promising safety and efficacy data, including a 96% overall response rate in treating B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. Despite the positive advancements, Mustang faced a net loss of $77.5 million and a decrease in cash reserves year-over-year. The company anticipates further data disclosures and escalation to final dose levels in ongoing clinical trials in 2023.
Read more →MBIOMustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium
Mustang Bio, Inc. will participate in Cantor's The Future of Oncology Virtual Symposium, with CEO Manuel Litchman leading a panel on CAR-T therapies for hematological malignancies. This opportunity highlights Mustang's focus on advancing cell and gene therapies for cancer and genetic diseases. The event is set for April 3, 2023, which could enhance Mustang's visibility in the oncology field.
Read more →MBIOMustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
Mustang Bio, Inc. will participate in the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023. The conference will showcase various healthcare companies focusing on new medicines and technologies, with discussions led by key opinion leaders. Mustang Bio, known for its work in cell and gene therapies, aims to advance its research and product development in the oncology field.
Read more →MBIOMustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across portfolio WORCESTER, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceut
Read more →MBIOMustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company f
Read more →MBIOMustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Enrollment continues in clinical trial of MB-106 under Mustang’s IND; next data disclosure anticipated 4Q 2022 Ongoing clinical trial of MB-106 at Fred Hutch continues to demonstrate high efficacy, durable responses, and favorable safety profile across wide range of hematologic
Read more →MBIOMustang Bio to Participate in Upcoming September 2022 Investor Conferences
WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia
WORCESTER, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy
94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted CAR T therapy 100% overall response rate in other B-cell non-Hodgkin lymphomas including Waldenstrom macroglobulinemia and
Read more →MBIOMustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants with XSCID treated with gene therapy presented at the 25th Annual Meeting of the American Society of Gene & Cell Therapy WORCE
Read more →MBIOMustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress
Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Mus
Read more →MBIOMustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors a
Read more →MBIOMustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting
Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to date Seventeen of 18 patients with follow-up greater than 6 months achieved robust immune reconstitution All 23 treated pati
Read more →MBIOMustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability observed, including patients with Waldenstrom macroglobulinemia and those who received prior CD19-directed CAR T therapy Expect to dose first patient in multicenter
Read more →MBIOCONSULTING AGREEMENT This Consulting Agreement (the "Agreement") is made effective as of
CONSULTING AGREEMENT Consulting Agreement (the "Agreement") is made effective as of March 17, 2022 (the "Effective Date"), by and between Mustang Bio, Inc., a Delaware corporation, with its principal place of business being 377 Plantation Street, Worcester, MA 01605 (the "Comp
Read more →MBIOMustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations
WORCESTER, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Participate in Three March 2022 Investor Conferences
WORCHESTER, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor
Read more →MBIOMustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
WORCESTER, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital
WORCESTER, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOLOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this " Agreement ") dated as of
This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this "Agreement") dated as of March 4, 2022 (the "Closing Date") is entered into among MUSTANG BIO, INC., a Delaware corporation ("Borrower Representative"), and each
Read more →MBIOMustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
WORCESTER, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards
WORCESTER, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
WORCESTER, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Participate in Three January 2022 Virtual Investor Conferences
WORCESTER, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Added to the NASDAQ Biotechnology Index
WORCESTER, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of Hematology (ASH) Annual Meeting Key opinion leader conference call on Thursday, Decembe
Read more →MBIOMustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET WORCESTER, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene t
Read more →MBIOMustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency
Agreement expands Mustang’s pipeline of lentiviral gene therapies for SCID Preclinical development of additional targets to continue at Leiden University WORCESTER, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharma
Read more →MBIOMustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
WORCESTER, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas
WORCESTER, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Participate in Chardan’s Virtual 5th Annual Genetic Medicines Conference
WORCESTER, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Participate in Three September 2021 Investor Conferences
WORCESTER, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology
The exclusively licensed platform has potential application for any tumor target Preclinical development to continue at Mayo Clinic Mustang to file IND upon identification of a lead CAR construct WORCESTER, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”)
Read more →MBIOMustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
WORCESTER, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive
WORCESTER, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Present at the Raymond James Human Health Innovation Conference
WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in patients treated with modified cell manufacturing process Key opinion leader we
Read more →MBIOMustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Webinar to be held Tuesday, June 15, 2021, at 1:00 p.m. ET WORCESTER, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies
Read more →MBIOMustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors a
Read more →MBIOMustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress
WORCESTER, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors a
Read more →MBIOMustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is expected to begin enrolling patients in the third quarter of this year WORCESTE
Read more →MBIOMustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
WORCESTER, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rar
Read more →MBIOMustang Bio to Participate in Three March 2021 Virtual Investor Conferences
WORCESTER, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day
WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy WORCESTER, Mass., Feb. 02, 20
Read more →MBIOMustang Bio to Participate in Three January 2021 Virtual Investor Conferences
WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Data presented at the 62nd American Society of Hematology (ASH) Annual Meeting show extremely favorable safety profile and clinical activity 89% overall response rate and 44% complete response rate in patients treated with modified cell manufacturing process Key opinion leader
Read more →MBIOMustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
WORCESTER, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
WORCESTER, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
WORCESTER, Mass. and MUNICH, Germany, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic ca
Read more →MBIOMustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
WORCESTER, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer
WORCESTER, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat
WORCESTER, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Licenses LentiBOOST™ Technology from SIRION Biotech
WORCESTER, Mass. and MARTINSRIED, Germany, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO) and SIRION Biotech GmbH (“SIRION”) today announced a licensing agreement under which Mustang has acquired rights to SIRION’s LentiBOOST™ technology for the de
Read more →MBIOMustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)
WORCESTER, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Participate in Chardan’s Virtual 4th Annual Genetic Medicines Conference 2020
WORCESTER, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
WORCESTER, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Participate in Three September 2020 Virtual Investor Conferences
WORCESTER, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
WORCESTER, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients
WORCESTER, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Present at the Virtual Fortress Biotech Corporate Access Summit
WORCESTER, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency
WORCESTER, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Pricing of Public Offering of Common Stock
WORCESTER, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Proposed Public Offering of Common Stock
WORCESTER, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio to Host Virtual Annual Meeting of Stockholders
WORCESTER, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
Read more →MBIOMustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy
WORCESTER, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors a
Read more →MBIOMustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors a
Read more →MBIOMustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rar
Read more →MBIOMustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rar
Read more →MBIOMustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106
NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID Enhanced transduction procedure is demonstrating improvements in older patients with XSCID who received p
Read more →MBIOMustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference
NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting
St. Jude Children’s Research Hospital and the National Institutes of Health to present updated MB-107 clinical data for the treatment of X-linked severe combined immunodeficiency Fred Hutchinson Cancer Research Center to present overview of ongoing MB-106 Phase 1/2 clinical tria
Read more →MBIOMustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma
NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma
NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio to Participate in October 2019 Investor Conferences
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rar
Read more →MBIOMustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rar
Read more →MBIOMustang Bio to Present at Scientific Conferences in September 2019
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rar
Read more →MBIOMustang Bio to Present at September 2019 Investor Conferences
NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy
NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio and St. Jude Children’s Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA
RMAT designation follows positive Phase 1/2 clinical data published in the New England Journal of Medicine Designation to facilitate expedited development and review of MB-107 for XSCID NEW YORK and MEMPHIS, Tenn., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (NASDAQ: MB
Read more →MBIOMustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases
NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio to Present at 11th Annual Bioprocessing Summit
NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia
NEW YORK, July 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio and St. Jude Children’s Research Hospital to Participate in Panel Discussion at Boston CEO 2019
NEW YORK, and MEMPHIS, Tenn., May 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so
Read more →MBIOMustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma
NEW YORK and COLUMBUS, Ohio, May 16, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol
Read more →MBIOMustang Bio to Present at the Cell & Gene Therapy USA Congress 2019
NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Announces Full Exercise of Option
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare
Read more →MBIOMustang Bio to Present at the World Orphan Drug Congress USA 2019
NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rar
Read more →MBIOMustang Bio Announces $20 Million Venture Debt Financing Agreement with Horizon Technology Finance
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rar
Read more →MBIOMustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rar
Read more →MBIOMustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference
NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today
Read more →MBIOMustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme
Phase 1 trial underway at the University of Alabama at Birmingham in recurrent glioblastoma multiforme Mustang intends to combine the oncolytic virus (C134) with MB-101 (IL13Rα2-specific CAR) to potentially enhance efficacy in treating glioblastoma multiforme NEW YORK and COLUM
Read more →MBIOMustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
NEW YORK, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today
Read more →MBIOMustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (“CAR T”) technology and gene therapies for rare diseases, toda
Read more →MBIOMustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (“CAR T”) technology and gene therapies for rare diseases, toda
Read more →MBIOMustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope
First-of-its-kind Phase 1 clinical trial using intraventricular delivery of CAR T cells to brains of patients with HER2-positive breast cancer with brain metastases now enrolling patients First patient dosed in Phase 1 clinical trial of HER2-specific memory-enriched T cells in t
Read more →MBIOMustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today
Read more →MBIOMustang Bio to Present at 8th Annual Partnering Forum at Cell & Gene Meeting on the Mesa
NEW YORK, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene the
Read more →MBIOMustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene th
Read more →MBIOMustang Bio to Participate in September Investor Conferences
NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene the
Read more →MBIOMustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene the
Read more →MBIOMustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency
NEW YORK and MEMPHIS, Tenn., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) tech
Read more →MBIOMustang Bio to Present at 10th Annual Bioprocessing Summit
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today annou
Read more →MBIOMustang Bio Completes Pre-IND Meeting with FDA for MB-102 (CD123 CAR T)
NEW YORK, July 19, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced tod
Read more →MBIOMustang Bio Added to Russell 2000 , 3000 and Microcap Indexes
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announc
Read more →MBIOMustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass.
NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announc
Read more →MBIOMustang Bio to Present at June Investor Conferences
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announce
Read more →MBIOMustang Bio Announces Preclinical Data on Potency of its CAR T Cells in Glioblastoma Published in JCI Insight
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announce
Read more →MBIOMustang Bio Reports First Quarter 2018 Financial Results
NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR-T) technology, today announce
Read more →MBIOMustang Bio to Present at Biotech Innovations Conference
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR-T) technology, today announ
Read more →MBIOMustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announ
Read more →MBIOMustang Bio to Present at CAR-T Congress USA
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR-T) technology, today announ
Read more →MBIOMustang Bio Announces Key Leadership Appointments
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announ
Read more →MBIOMustang Bio to Present at March Investor Conferences
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announ
Read more →MBIOMustang Bio to Present at the 255th American Chemical Society National Meeting & Exposition
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announ
Read more →MBIOMustang Bio to Participate in Immuno-Oncology Panel at BIO CEO & Investor Conference
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announc
Read more →MBIOMustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (“CAR T”) technology, today annou
Read more →MBIOMustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial
Trial investigators at City of Hope announce first-reported complete response from a CAR T therapy in a BPDCN patient, additional complete response achieved in AML Investigators found infusions of MB-102 are safe and well tolerated Data presented by City of Hope in oral session
Read more →MBIOMustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies
NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (“CAR T”) technology, today annou
Read more →MBIOMustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller
NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech, Inc. (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today a
Read more →MBIOMustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announc
Read more →MBIOMustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announc
Read more →MBIOMustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain
NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced tha
Read more →MBIOMustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts
Facility located in the UMass Medicine Science Park will support clinical development and commercialization of CAR T pipeline Preparations underway for clinical production in 2018 NEW YORK, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortres
Read more →MBIOMustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma
NEW YORK, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech, Inc. (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today a
Read more →MBIOMustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
Entered license agreement with Fred Hutchinson Cancer Research Center for CD20-directed CAR T Initiation of Phase 1/2 investigator-initiated trial in B-cell non-Hodgkin lymphomas planned for fourth quarter 2017 NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mu
Read more →MBIOMustang Bio to Present at the CAR-TCR Summit 2017
NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announ
Read more →MBIOMustang Bio Commences Trading on the NASDAQ Global Market
NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced tha
Read more →MBIOMustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announced financial r
Read more →MBIOCorporate Presentation June 2017 Forward Looking Safe Harbor Statement This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements
Corporate Presentation June 2017 Forward Looking Safe Harbor Statement This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements are often, but not always, made through the use of words o
Read more →MBIOMustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
NEW YORK, May 15, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announced financial re
Read more →MBIOMustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
NEW YORK, April 24, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Manuel Litchman, M.D., has been appointed President and Chief Executive Officer. Dr. Litchman has also joined Mustang’s Board of Directors. M
Read more →MBIOCORPORATE OVERVIEW NASDAQ : FBIO October 2016
CORPORATE OVERVIEW NASDAQ : FBIO October 2016 FORWARD - LOOKING STATEMENTS Statements in this presentation that are not descriptions of historical facts are forward - looking statements within the meaning of the " safe harbor " provisions of the Private Securities Litigation Ref
Read more →MBIOMustang Bio Announces Oral Presentation of Initial Clinical Data for MB-101 (IL13Ra2-specific CAR T cells) by City of Hope Investigators at the American Society of Gene and Cell Therapy 19th Annual Meeting
NEW YORK, May 05, 2016 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that an oral presentation related to its MB-101 (IL13Rα2-specific CAR T cells) product candidate in development was presented by City of Hope (“COH”
Read more →MBIOMustang Bio Announces Presentations of MB-101, a Novel IL13Ra2-specific CAR-T cells Product in Clinical Development, at the American Society of Gene and Cell Therapy 19th Annual Meeting
NEW YORK, April 18, 2016 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that two abstracts pertaining to its MB-101 (IL13Rα2-specific CAR-T cells) product candidate in development were selected for presentation at the
Read more →Competitive Position
How MBIO ranks across every disease it competes inCompetitive Position is a premium feature
See how MBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial